布拉酵母菌

研究概述

• 保護腸胃，減輕腸易激綜合症和腹瀉
  體內有白色念珠菌之類的真菌是自然的。 但是，如果其數量過多，則可能引起胃腸道（食道，胃，腸和直腸）感染。 研究顯示，布拉酵母菌可以平衡和抑制這種有害的真菌， ^{[1] </ sup>} 與抗生素相關的腹瀉（antibiotic-associated diarrhea，AAD），^[2]以及感染性和功能性腹瀉。^[3] 在1995年一項雙盲、安慰劑對照的研究中，將193人分為服用布拉酵母菌和安慰劑的組別。 在服用益生菌的97位患者中，有7位（7.2％）報告了腹瀉，而在服用安慰劑的96位患者中，有14位（14.6％）患有腹瀉。^[4]一項研究將酸奶與布拉酵母菌對抗腹瀉進行了比較，發現益生菌的腹瀉持續時間比酸奶短。^[5]   可以通過布拉酵母菌的益生菌混合物緩解或預防，更嚴重的胃腸道問題，包括腸易激綜合症，^[6]結腸癌^[7][8]，以及腸屏障功能改變疾病。^[9]腸易激綜合徵是由腸道微生物的變化引起的。2015年對總共1793名患者的薈萃分析證實，益生菌可有效緩解疼痛和症狀的嚴重程度，如腹脹（腹部腫大）和腸胃氣脹（通過氣體）。^[10]預防結腸癌的其中一種方法是，保持腸道健康。 一項大規模研究顯示，益生菌通過酸奶可以幫助45241名受試者大大降低了患結腸癌的風險。^[11]   研究評分：非常可靠
• 可能改善心血管健康
  2016年的一項研究回顧了益生菌對心臟的影響。結論是，補充益生菌可以顯著降低心血管疾病的生物標誌物，例如低密度脂蛋白（壞膽固醇）、總膽固醇和炎症生物標誌物。 ^{[12] [13]}   研究評分： 看好
• 參考文獻
  1. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation., Krasowska A, Murzyn A, Dyjankiewicz A, Łukaszewicz M, Dziadkowiec D., FEMS yeast research, 2009 2. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL., The American Journal of Gastoenterology, 1995, Am J Trop Med Hyg. 2010 Mar; 82(3): 488–491. doi: 10.4269/ajtmh.2010.09-0529 3. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption., Terciolo C1,2, Dapoigny M3, Andre F4., Clin Exp Gastroenterol. 2019 Feb 11;12:67-82. doi: 10.2147/CEG.S181590. eCollection 2019. 4. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL., The American Journal of Gastoenterology, 1995, Am J Trop Med Hyg. 2010 Mar; 82(3): 488–491. doi: 10.4269/ajtmh.2010.09-0529 5. Clinical Efficacy Comparison of Saccharomyces boulardii and Yogurt Fluid in Acute Non-Bloody Diarrhea in Children: A Randomized, Controlled, Open Label Study, Makbule Eren,* Ener C. Dinleyici, and Yvan Vandenplas, 6. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World Journal of Gastroenterology?: WJG. 2015;21(10):3072-3084. doi:10.3748/wjg.v21.i10.3072. 7. Pala V, Sieri S, Berrino F, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer. 2011;129(11):2712-9. 8. Clinical Efficacy Comparison of Saccharomyces boulardii and Yogurt Fluid in Acute Non-Bloody Diarrhea in Children: A Randomized, Controlled, Open Label Study, Makbule Eren, Ener C. Dinleyici, and Yvan Vandenplas, 9. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption., Terciolo C1,2, Dapoigny M3, Andre F4., Clin Exp Gastroenterol. 2019 Feb 11;12:67-82. doi: 10.2147/CEG.S181590. eCollection 2019. 10. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World Journal of Gastroenterology?: WJG. 2015;21(10):3072-3084. doi:10.3748/wjg.v21.i10.3072. 11. Pala V, Sieri S, Berrino F, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer. 2011;129(11):2712-9. 12. Thushara RM, Gangadaran S, Solati Z, Moghadasian MH. Cardiovascular benefits of probiotics: a review of experimental and clinical studies. Food Funct. 2016;7(2):632-42. 13. Intersections between Microbiome and Heart Failure: Revisiting the Gut Hypothesis, Yuji Nagatomo, MD, PhD and W. H. Wilson Tang, MD, J Card Fail. 2015 Dec; 21(12): 973–980., Published online 2015 Oct 3. doi: 10.1016/j.cardfail.2015.09.017